Latin American consensus on the medical oncologic management of early-stage HR+/HER2− breast cancer: Addressing regional disparities in Spanish-speaking countries

Landaverde D.U.; Petracci F.; Grano de Oro A.; Bravo Garzón M.A.; Estévez M.; Arce-Salinas C.; González I.; Veliz I.; Amador J.L.; Castillo O.; Enciso V.; Codas L.; Valencia F.; Gálvez M.; Valentín-Bejarano J.; Sánchez S.; Lemes-Pistón V.; Hannois D.; Khanna P.; Miranda J.P.; Guillen G.; Sánchez-Bayona R.; Gavilá-Gregori J.; Vidal-Losada M. · Breast (2026) · DOI: 10.1016/j.breast.2026.104865

Resumen

Purpose: Substantial disparities persist in managing early-stage hormone receptor-positive, HER2−negative (HR+/HER2−) breast cancer across Spanish-speaking Latin America, including limited access to genomic testing, systemic therapies, and fertility preservation. The Latin American Breast Cancer Association (LABCA) convened an expert panel to produce the first consensus tailored to Spanish-speaking countries. Methods: A literature review (Embase, PubMed, Scopus, ClinicalKey, LILACS; 2014–2025), informed by ESMO/ASCO/NCCN/SEOM guidelines and registered in PROSPERO (CRD42024565706), supported statement development. A steering committee of three experts of Spanish nationality supervised the process. Twenty-one specialists from 11 countries participated in a modified Delphi process; 31 items were voted in Round 1 and 25 statements were retained within scope. Consensus was pre-defined as ≥80% agreement (or median 7–9), with a mean/outlier rule reported alongside. Results: Applying the ≥80% rule, 22 of 25 statements (88%) reached full consensus; three (1.3, 2.4, 3.3; 75–76%) were near-consensus and retained with caveats. Recommendations integrated clinicopathologic and molecular factors to guide risk stratification; genomic assays were reserved for selected scenarios and discouraged in very low-risk tumors or ≥4 positive lymph nodes. Consensus also covered ovarian suppression plus endocrine therapy, fertility preservation, sexual-health and genetic evaluation, and adjuvant CDK4/6 and PARP inhibitors when accessible. Marked heterogeneity in access was documented by country and sector. Conclusion: This consensus provides the first region-specific, evidence-based, resource-adapted recommendations for early-stage HR+/HER2− breast cancer in Spanish-speaking Latin America, aiming to reduce disparities and strengthen equitable oncology care.